Skip to content

Exploration of the active components and mechanisms of Kaixuan Tongluo Method in the treatment of sepsis-induced acute lung injury based on Xuanfu-Luocollateral Theory integrating computational simulation and clinical research

Exploration of the active components and mechanisms of Kaixuan Tongluo Method in the treatment of sepsis-induced acute lung injury based on Xuanfu-Luocollateral Theory integrating computational simulation and clinical research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001652
Enrollment
Unknown
Registered
2026-07-06
Start date
2026-07-06
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis-induced acute lung injury

Interventions

Control group:Conventional Western medicine treatment combined with placebo
Experimental group (Kaixuan Tongluo Method group):Conventional Western medicine treatment combined with Kaixuan Tongluo Decoction

Sponsors

Wenzhou Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age range: 17 - 80; 2) Meets the diagnostic criteria of both traditional Chinese and Western medicine; 3) The time from onset to seeking medical treatment is less than 48 hours; 4) Has primary diseases such as infections in the respiratory, digestive, and urinary systems; 5) The patient or their family has given informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with severe liver or kidney dysfunction or severe cardiovascular diseases; 2) Patients who died within 48 hours of admission; 3) Patients with lung damage caused by other non-sepsis factors, such as trauma, paraquat, other severe conditions, etc.; 4) Patients who cannot cooperate with treatment; 5) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
phosphatidylinositol 3-kinase;

Secondary

MeasureTime frame
Blood Routine;Urinalysis;Stool routine test;Alanine Aminotransferase;Aspartate aminotransferase;creatinine;Creatine kinase isoenzyme MB;lactic acid;Calcitonin;B-type natriuretic peptide;Coagulation Profile;

Countries

china

Contacts

Public Contactfangpeng

Wenzhou Hospital of Chinese Medicine

985126100@qq.com15243618183

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026